TransMedics Group, Inc. — Director's Dealing 2022

Feb 24, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2022-02-22

Reporting Person: Gordon Stephen (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-22	Stock Option (Right to Buy)	$13.28	A	52000	Acquired	2032-02-22	Common Stock (52000)	Direct

Footnotes

F1: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026.